Skip to main content

Table 2 Changes in the therapeutic agents used, by age group

From: Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020

 

<60

60–69

70–79

≥ 80

Total

Number

2459

2619

2957

1264

9299

MTX use (%)

1718 (69.9)

1750 (66.8)

1665 (56.3)

516 (40.8)

5649 (60.6)

 Dose (s.d.)

8.38 (4.40)

7.87 (4.36)

7.06 (3.89)

5.13 (3.83)

7.60 (4.23)

PRED use (%)

507 (20.6)

615 (23.5)

892 (30.2)

649 (51.3)

2663 (28.6)

 Dose (s.d.)

4.91 (2.52)

4.41 (2.42)

4.42 (2.66)

4.51 (3.16)

4.53 (2.67)

bDMARDs (%)

713 (28.9)

651 (24.8)

633 (21.4)

228 (18.0)

2224 (23.9)

TNFi (%*)

480 (67.3)

418 (64.2)

329 (49.6)

132 (57.8)

1354 (60.9)

IL6Ri (%*)

203 (28.5)

175 (26.9)

171 (27.0)

12 (5.3)

561 (25.2)

Abatacept (%*)

30 (4.2)

58 (8.9)

133 (21.0)

84 (36.8)

309 (13.9)

tsDMARDs (%)

50 (2.0)

31 (1.2)

64 (2.2)

21 (1.7)

166 (1.8)

  1. %* means percentage of the drug in used b/ts DMARDs
  2. Abbreviations: MTX methotrexate, s.d. standard deviation, PRED prednisolone, bDMARDs biological disease-modifying anti-rheumatic drugs, TNFi tumor necrosis factor inhibitor, IL6Ri interleukin-6 receptor inhibitor, tsDMARDs targeted synthetic disease-modifying anti-rheumatic drugs